NodThera rebrands to Rezera, plans Phase 3 trial in peripheral artery disease in 2027 with ~800 patients testing NLRP3 inhibitor ruvonoflast.
After tinkering with the biology of the broadly appealing anti-inflammatory NLRP3 pathway, NodThera is now plotting its pivotal trial plans for 2027.
…
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
A novel NLRP3 inhibitor reduced high-sensitivity C-reactive protein and other inflammatory biomarkers in patients at high…
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in…
Novartis' Rhapsido cuts MS relapse rates and shows a clean safety profile in Phase 3 trials; Jefferies sees peak sales above $3B.
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly…
RenovoRx finishes Phase 3 TIGeR-PaC trial enrollment for locally advanced pancreatic cancer, expecting topline data in H2 2027.
NorthLinks Bio, backed by RA Capital with $34M, is advancing HEX17 — an intranasal broad-spectrum viral prophylactic from…
